Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunocore Holdings plc IMCR

Healthcare Biotechnology
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and... see more

Recent & Breaking News (NDAQ:IMCR)

Immunocore to present at upcoming investor conferences

GlobeNewswire 8 hours ago

Immunocore reports third quarter financial results and provides a business update

GlobeNewswire 2 days ago

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

GlobeNewswire September 14, 2024

Immunocore to present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 12, 2024

Immunocore announces transition of Chief Financial Officer

GlobeNewswire August 29, 2024

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire August 8, 2024

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

GlobeNewswire August 1, 2024

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

GlobeNewswire June 18, 2024

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

GlobeNewswire June 1, 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

GlobeNewswire May 31, 2024

Immunocore to present at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

GlobeNewswire May 29, 2024

Immunocore reports first quarter financial results and provides a business update

GlobeNewswire May 8, 2024

Immunocore announces upcoming presentation and posters at ASCO 2024

GlobeNewswire April 24, 2024

Immunocore to present at upcoming investor conferences

GlobeNewswire April 4, 2024

Immunocore presented two posters at CROI 2024

GlobeNewswire March 5, 2024

Immunocore to present at upcoming investor conferences

GlobeNewswire March 1, 2024

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

GlobeNewswire February 28, 2024

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

GlobeNewswire February 22, 2024

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

GlobeNewswire February 21, 2024